The pharmaceutical excipient provider Roquette, has unveiled an investment plan of €25 million for liquid and powder polyols between 2022 and 2024 at its site in Lestrem, France. This investment is meant to establish a reliable supply in the long run and strengthen Roquette’s position as a provider of polyols.

Roquette’s site in Lestrem is the largest polyol plant in the world offering a wide variety of products. This investment will improve equipment efficiency and increase safety standards. It will also help to standardize some industrial operations contributing to an overall production performance improvement. This evolution is designed to ensure a sustainable supply in the market and meet customers’ increasing expectations for greater flexibility.

Polyols as key products for the pharmaceutical market
Polyols are key excipients for the pharmaceutical sector in oral dosage forms. Directly compressible, polyols help the formulation of all types of tablets, and some are adapted for swallowable, chewable, or dispersible or effervescent tablets. The higher purity grades are also active pharmaceutical ingredients (APIs) approved by worldwide drug administrations, and widely used in injectable solutions or in dialysis applications.

“Today, Roquette is recognized as a global leader in polyols,” said Pascal Leroy, senior vice-president of core ingredients, Roquette. “We are uniquely positioned to address customers’ needs as we strive to be the best partner for the polyols markets, offering a wide range, very well adapted to all markets and backed by a global service and technical assistance network. Thanks to this investment, we will now strengthen the reliability of the supply and our global industrial footprint.”